Clinical Trial Update: REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction [Phase 2]

View source ↗

Summary

Regeneron reports termination of the Phase 2 trial of REGN5381 in adults with heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• REGN5381

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Heart Failure | Phase 2 | Status: TERMINATED